TOLREMO therapeutics Company
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Connections
Headquarters:
Zürich, Zurich, Switzerland, Europe
Founded Date:
2017-01-01
Industry:
Drug Discovery & Development
Employee Number:
11-50
Super Industry:
Biopharma & Life Science Tools
Investors:
Altos Ventures, BioMedPartners, Pierre Fabre Invest, Z?rcher Kantonal Bank, redalpine
Ipo Status:
private
City:
Zürich
Region:
Zurich
Country:
Switzerland
Founders:
Emmanuel Savioz, Isaac Kobrin, Karl-Heinz Altmann, Stefanie Flückiger-Mangual, Wilhelm Krek